However, a recent study could not verify a correlation between the LRRK2 mutation and the development of malignant melanomas in either symptomatic PD patients or asymptomatic carriers, and no SNCA gene was identified in patients with a malignant melanoma history [269]. This evidence concerns the gene SNCA and melanoma.